View Post

Breast cancer breakthrough: Sarah Cannon discusses newly FDA-approved immunotherapy

Spring brings new hope and new beginnings, and for breakthroughs in cancer treatment, this season is off to a promising start. Earlier this month, the U.S. Food and Drug Administration (FDA) approved the first-ever immunotherapy (atezolizumab), in combination with chemotherapy, for the treatment of breast cancer. “Immunotherapy is a drug that we’ve been using in…
View Post
sarah cannon
View Post

A look ahead to 2018 advancements in cancer research with Dr. Spigel

There were many exciting developments in cancer research and care in 2017, including advances in immunotherapy, precision medicine, and prevention. David Spigel, MD, Chief Scientific Officer; Director of Lung Cancer Research Program at Sarah Cannon, HCA’s global cancer institute, recently discussed on Fox & Friends innovations made in the past year, and what is on…
View Post
View Post

Sarah Cannon Featured on Fox & Friends

Sarah Cannon cancer experts and leadership appeared on Fox & Friends on Wednesday, April 29 to discuss the encouraging advances being made in cancer care. Sarah Cannon, HCA’s global cancer enterprise, is a world leader in clinical trials and immunotherapy, conducting more than 500 clinical trials annually. In the Fox & Friends segment, Sarah Cannon’s…
View Post